ITGB6: Integrin beta-6
Integrin alpha-V:beta-6 (ITGAV:ITGB6) is a receptor for fibronectin and cytotactin.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ITGB6, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Antibody-drug conjugate 1
| Sigvotatug vedotin | Phase 3 | Pfizer | Antibody-drug conjugate | Binding agentIntegrin beta-6 binding agent | 4 |
| Sigvotatug | Phase 2 | Pfizer | Antibody | InhibitorIntegrin beta-6 inhibitor | 4 |
| Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | Sigvotatug, Sigvotatug vedotin | Phase 1 / Phase 2 | Recruiting | Pfizer | Nov 12, 2025 |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Sigvotatug, Sigvotatug vedotin | Phase 3 | Recruiting | Pfizer | Jan 3, 2025 |
| A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | Sigvotatug, Sigvotatug vedotin | Phase 3 | Active, not recruiting | Seagen, a wholly owned subsidiary of Pfizer | Aug 25, 2023 |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Sigvotatug, Sigvotatug vedotin | Phase 1 | Recruiting | Seagen, a wholly owned subsidiary of Pfizer | May 15, 2020 |
- Amelogenesis imperfecta0.61
- Amelogenesis imperfecta type 10.61
- Smoking initiation0.40
- Alopecia - intellectual disability syndrome0.39
- Hypocalcified amelogenesis imperfecta0.37
- Non-small cell lung carcinoma0.34
- Metabolic syndrome0.34
- Anxiety disorder0.33
- Membranous glomerulonephritis0.33
- Adolescent idiopathic scoliosis0.33
- Atrial fibrillation0.24
- Type 2 diabetes mellitus0.21
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4876, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P18564, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets